SEARCH

SEARCH BY CITATION

References

  • 1
    Hirota S, Isozaki K, Moriyama Y et al. Gain-of-function mutations of KIT in human gastrointestinal stromal tumors. Science 1998; 279: 57780.
  • 2
    Rubin BP, Singer S, Tsao C et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001; 61: 811821.
  • 3
    Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004; 22: 381325.
  • 4
    Longley BJ, Tyrrell L, Lu S-Z et al. Somatic KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 1996; 12: 31214.
  • 5
    Longley BJ Jr, Metcalfe DD, Tharp M et al. Activating and dominant inactivating KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci 1999; 96: 160914.
  • 6
    Gari M, Goodeve A, Wilson G et al. KIT proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. Br J Haematol 2001; 105: 894900.
  • 7
    Jiao B, Wu C, Liang Y et al. AML1-ETO9a is correlated with KIT overexpression/mutations and indicates poor disease outcome in t (8; 21) acute myeloid leukemia-M2. Leukemia 2009; 23: 1598604.
  • 8
    Tian Q, Frierson HF, Krystal GW, Moskaluk CA. Activating KIT gene mutations in human germ cell tumors. Am J Pathol 1999; 154: 16437.
  • 9
    Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006; 24: 43406.
  • 10
    Debiec-Rychter M, Sciot R, Le Cesne A et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006; 42: 1093103.
  • 11
    Heinrich MC, Corless CL, Demetri GD et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21: 43429.
  • 12
    Antonescu CR, Besmer P, Guo T et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005; 11: 418290.
  • 13
    Heinrich MC, Corless CL, Blanke CD et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006; 24: 476474.
  • 14
    Debiec-Rychter M, Cools J, Dumez H et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 2005; 128: 2709.
  • 15
    Maki R, Fletcher J, Heinrich M et al. Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST). J Clin Oncol (ASCO Annual Meeting Proceedings, Meeting Abstracts) 2005; 23 (Suppl. 16): 9011.
  • 16
    Demetri GD, van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368: 132938.
  • 17
    Gajiwala KS, Wu JC, Christensen J et al. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci 2009; 106: 15427.
  • 18
    Heinrich MC, Maki RG, Corless CL et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 2008; 26: 53529.
  • 19
    Growney JD, Clark JJ, Adelsperger J et al. Activation mutations of human KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood 2005; 106: 721.
  • 20
    Ma Y, Zeng S, Metcalfe DD et al. The KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 2002; 99: 17414.
  • 21
    Pardanani A, Elliott M, Reeder T et al. Imatinib for systemic mast-cell disease. Lancet 2003; 362: 5356.
  • 22
    Luo H, Quan H, Xie C, Xu Y, Fu L, Lou L. HH-GV-678, a novel selective inhibitor of BCR-ABL, outperforms imatinib and effectively overrides imatinib resistance. Leukemia 2010; 24: 18079.
  • 23
    Xiang Z, Kreisel F, Cain J, Colson A, Tomasson MH. Neoplasia driven by mutant KIT is mediated by intracellular, not plasma membrane, receptor signaling. Mol Cell Biol 2007; 27: 26782.
  • 24
    Sambrook J, Russell DW. Molecular Cloning: A Laboratory Manual (Chinese version), Chapter 13. Beijing: Cold Spring Harbor Laboratory Press, 2001; 10959.
  • 25
    Yang Y, Liu K, Zhong D, Chen X. Simultaneous determination of flumatinib and its two major metabolites in plasma of chronic myelogenous leukemia patients by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2012; 895-896: 2530.
  • 26
    Wang Y-Y, Zhou G-B, Yin T et al. AML1-ETO and KIT mutation/overexpression in t (8; 21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci USA 2005; 102: 11049.
  • 27
    Kemmer K, Corless CL, Fletcher JA et al. KIT mutations are common in testicular seminomas. Am J Pathol 2004; 164: 305.
  • 28
    Mol CD, Dougan DR, Schneider TR et al. Structural basis for the autoinhibition and STI-571 inhibition of KIT tyrosine kinase. J Biol Chem 2004; 279: 3165563.
  • 29
    Wardelmann E, Thomas N, Merkelbach-Bruse S et al. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol 2005; 6: 24951.
  • 30
    Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005; 44: 87994.
  • 31
    Goodman VL, Rock EP, Dagher R et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 2007; 13: 136773.
  • 32
    Montemurro M, Schöffski P, Reichardt P et al. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur J Cancer 2009; 45: 22937.
  • 33
    Schittenhelm MM, Shiraga S, Schroeder A et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006; 66: 47381.
  • 34
    Guida T, Anaganti S, Provitera L et al. Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor β gatekeeper mutants. Clin Cancer Res 2007; 13: 33639.
  • 35
    Heinrich MC, Marino-Enriquez A, Presnell A et al. Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors. Mol Cancer Ther 2012; 11: 177080.
  • 36
    Tarn C, Merkel E, Canutescu AA et al. Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling. Clin Cancer Res 2005; 11: 366877.
  • 37
    Azam M, Seeliger MA, Gray NS, Kuriyan J, Daley GQ. Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol 2008; 15: 110918.
  • 38
    Duveau DY, Hu X, Walsh MJ et al. Synthesis and biological evaluation of analogues of the kinase inhibitor nilotinib as ABL and KIT inhibitors. Bioorg Med Chem Lett 2013; 23: 6826.
  • 39
    Horio T, Hamasaki T, Inoue T et al. Structural factors contributing to the ABL/LYN dual inhibitory activity of 3-substituted benzamide derivatives. Bioorg Med Chem Lett 2007; 17: 271217.